New anticoagulants for prevention and treatment of venous thromboembolism

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 373-382

  Roberts, Lara N ^a   Arya, Roopen ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Dabigatran; Idraparinux; Rivaroxaban; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; BIOTIN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; RAZAXABAN; RIVAROXABAN; SSR 126517 E; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; BIOTINYLATION; BLEEDING; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DETERIORATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER FAILURE; LIVER TOXICITY; LUNG EMBOLISM; LUNG SCINTISCANNING; OUTCOME ASSESSMENT; PHLEBOGRAPHY; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MORPHOLINES; OLIGOSACCHARIDES; PYRIDINES; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77952895189     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112232     Document Type: Article

References (72)

1. Heit J, Silverstein M, Mohr D, Petterson T, O'Fallon W, Melton L. Estimated annual incidence of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) in the US. Blood 2005; 106: 267A.
2. House of Commons Health Committee. The prevention of venous thromboembolism in Hospitalised Patients. Second report of session 2004-2005. London: House of Commons. The Stationary Office, 2005. It can be accessed online at http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf
3. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the Postthrombotic syndrome. Arch Int Med 2004; 164: 17-26.
4. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107(Suppl1): I22-30.
5. th ed. Chest 2008; 133: 141-59.
6. Rosenberg R, Bauer K. The heparin-antithrombin system: a natural anticoagulant system. In: Colman RW, Hirsh J, Marder V, Clowes A, George JN, Eds. Haemostasis and Thrombosis: Basic principles and clinical practice. 4th ed. Philadelphia: Lippincott, 2001: pp. 711-32.
7. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight heparin and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73.
8. th ed.) Chest 2008; 133: 340-80.
9. Van Dongen CJ, van der Belt AG, Prins MHF, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins vs adjusted dose unfractionated heparin [review]. Cochrane Database Syst Rev 2004; 4: CD00II00.
10. Warkentin TE, Levine MN, Hirsh J, et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Eng J Med 1995; 332: 1330-5.
11. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum mineral bone density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-6.
12. Donat F, Duret J, Santoni A, et al. Pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41: 1-9.
13. Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A. A spectrum of partially carboxylated prothrombins in plasmas of coumarin-treated patients. Biochim Biophys Acta 1977; 494: 271-6.
14. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and γ-carboxyglutamic acid-deficient prothrombins. J Biol Chem 1985; 260: 279-87.
15. Ansell J, Hirsh J, Hylek E, Jacobsen A, Crowther M, Palareti G. Pharmacology and management of Vitamin K antagonists: The American College of Chest Physicians Evidence-based clinical practice guidelines 8th ed. Chest 2008; 133: 160-98.
16. Cosgriff SW. The effectiveness of an oral Vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy. Ann Int Med 1956; 45: 14-22.
17. Testa L, Andreotti F, Zoccai BGGL, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22639 patients. Int J Cardiol 2007; 122: 117-24.
18. th ed. Chest 2008; 133: 234-56.
19. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Invest Drugs 2006; 15: 843-55.
20. Turpie AGG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-47.
21. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 3806.
22. Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs 2007; 16: 431-40.
23. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-84.
24. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
25. Choay J, Petitou M, Lormeau JC, Simay P, Casu BJ, Gatti G. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
26. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004; 110: I19-26.
27. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
28. The Van Gogh Investigators. Idraparinux vs standard therapy for venous thromboembolic disease. New Engl J Med 2007; 357: 1094-104.
29. The Van Gogh Investigators. Extended prophylaxis of venous thromboembolism with Idraparinux. N Engl J Med 2007; 357: 1105-12.
30. Harenberg J, J rg I, Vukojevic Y, Mikus G, Weiss G. Anticoagulant effects of idraparinux after termination for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008; 64: 555-63.
31. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6: 1697-706.
32. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel anti-thrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
33. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
34. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-93.
35. Eriksson BI, Borris L, Dahl E, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-8.
36. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa for the prevention of venous thromboembolism after total knee replacement: a phase II dose ranging study. J Thromb Haemost 2005; 3: 2479-86.
37. Fisher WD, Bengt BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97: 931-7.
38. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement surgery. Circulation 2006; 114: 2374-81.
39. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
40. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
41. Kakkar AJ, Brenner B, Dahl OE, et al. Extended duration rivaroxaban vs short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: double-blind randomised controlled trial. Lancet 2008: 372: 31-9.
42. th ed). Chest 2008; 133; 381-453.
43. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor xa inhibitor rivaroxaban (BAY59-7939). Circulation 2007; 116: 180-7.
44. Buller HR. Once daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose finding study. Eur Heart J 2006; 27(Suppl): 761 Abstract.
45. Lassen MR, Davidson BL, Gallen A, Pineo G, Ansell J, Deitchman D. A Phase II randomised double blind, five arm, parallel group, dose-response study of the new oral directly acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003: 102: 15a.
46. He KH, He B, Grace JE, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. I (ASH Annual meeting Abstracts) Blood 2006; 108 Abstract 910.
47. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
48. On behalf of the Botticelli investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor Apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-8.
49. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001: 101: 171-81.
50. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
51. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip/knee replacement. Thromb Haemost 2003; 89: 288-96.
52. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
53. Fiessinger J-N, Huisman MV, Davidson BL, et al. Ximelagatran vs low molecular weight heparin for the treatment of deep vein thrombosis: a randomised trial. JAMA 2005; 293: 681-9.
54. Hauel NH, Nar H, Priepke H, Ries U, Stassen JH, Wienen W. Structure based design of novel potent non-peptide thrombin inhibitors. J Med Chem 2002; 45: 1757-66.
55. Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HWM. Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Thromb Haemost 2001; 86(Suppl): P755 [abstract].
56. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of oral direct thrombin inhibitor dabigitran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
57. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for the prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomised trial. J Thromb Haemost 2005; 3: 103-11.
58. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomised trial. J Thromb Haemost 2007; 5: 2178-85.
59. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate vs enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
60. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
61. De Cristafaro R, De Candida E. Thrombin domains: structure, function and interaction with platelet receptors. J Thromb Thromb 2003; 15: 151-63.
62. Coughlin S. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
63. Nylander S, Mattsson C, Ramstrom S, Lindahl TL. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 2004; 142: 1325-31.
64. Warkentin TE, Mauer BT, Aster RH. Heparin induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2563-4.
65. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban - an oral factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008; 143: 92-9.
66. Bjisterveld NR, Vink R, can Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653-8.
67. Geerts W. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008; 359: 2175.
68. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic disease adverse effects after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
69. Aledort LM. Comparative thrombotic incidence after infusion of recombinant factor VIIa vs factor VIII inhibitor bypassing activity. J Thromb Haemost 2004; 2: 1700-8.
70. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-61.
71. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
72. Lessened K-H, Schafer HG, Tokenize IF, Tillman C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-37.